# Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

> **NCT04930536** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 103 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib capsule

## Key facts

- **NCT ID:** NCT04930536
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-05-02
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930536, "Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04930536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*